This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medtronic Gets FDA Approval for Accurian RF Ablation Platform
by Zacks Equity Research
Medtronic's (MDT) RF ablation platform will use radio waves to provide relief from chronic pain.
Integra Rides on Channel Expansion Strategy, New Alliances
by Zacks Equity Research
Integra's (IART) success with its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
ResMed Inks Deal With PharMerica on Medication Management
by Zacks Equity Research
The deal between ResMed's (RMD) MatrixCare and PharMerica covers NCPDP (National Council for Prescription Drug Programs) Bidirectional ePrescribing with all MatrixCare customer facilities.
DexCom (DXCM) Gets Health Canada Approval for G6 CGM System
by Zacks Equity Research
DexCom's (DXCM) G6 CGM system intends to serve diabetes patients of all age groups in Canada.
Masimo (MASI) Q4 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Masimo (MASI) sees an increase in shipments of noninvasive technology in Q4.
Masimo and Saudi Arabia MOH Collaborate for CCHD Screening
by Zacks Equity Research
Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.
Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
by Zacks Equity Research
Focus on cloud-based services is likely to boost Veeva Systems' (VEEV) fiscal Q4 results.
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?
by Zacks Equity Research
Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.
Here's What Will Give Shape to Medtronic's (MDT) Q3 Earnings
by Zacks Equity Research
Medtronic (MDT) is expected to maintain a decent market share in the core pacing backed by the continued uptake of Micra Transcatheter Pacing System in Q3.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.
Can Canadian Market Drive Canopy Growth (CGC) Q3 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) is expected to benefit from solid top-line contribution from the Canadian medical cannabis market and the legalization of the recreational use of cannabis in Q3.
Can Global Industrial Unit Aid Ecolab's (ECL) Q4 Earnings?
by Zacks Equity Research
Ecolab's (ECL) preliminary Q4 earnings are likely to fall short of estimates.
3 Medical Instruments Stocks Likely to Beat Estimates in Q4
by Zacks Equity Research
Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
Why Masimo (MASI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stock Market News For Jan 10, 2019
by Zacks Equity Research
Wall Street rallied for the fourth successive day owing to positive developments on the trade front and Fed Chair???s indication of maintaining caution on further interest rate hikes.
Masimo's (MASI) Preliminary Results for 2018 Cheer Investors
by Zacks Equity Research
Masimo (MASI) issues guidance for 2019. It anticipates witnessing strong contribution from its core product revenue segment.
Here's Why Investors Should Hold Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.
Masimo (MASI) Down 3.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Bet on DexCom (DXCM) Right Now
by Zacks Equity Research
DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.
Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes
by Zacks Equity Research
Thermo Fisher (TMO) is registering a sturdy global footprint with strong growth seen in Asia-Pacific including China.